ALEUP.PA stock plunges 18.18% on April 20, 2026 as Europlasma faces losses

ALEUP.PA stock collapsed today, dropping 18.18% to close at €0.018 on EURONEXT. Europlasma S.A., the French waste management and plasma solutions company, continues its downward spiral with a market cap of just €48,231. The stock has lost 99.95% over the past year, reflecting severe operational challenges. Trading volume surged to 21 million shares, quadruple the average, signaling panic selling. With negative earnings of -€88.61 per share and persistent losses, ALEUP.PA stock remains under intense pressure as investors flee the struggling industrial firm.

ALEUP.PA Stock Price Collapse: Today’s Market Action

ALEUP.PA stock opened at €0.018 and closed at the same level after a brutal 18.18% intraday decline. The stock traded between €0.0168 and €0.0186, showing extreme volatility. Volume exploded to 21.01 million shares, compared to the 16.81 million average, indicating forced liquidations and panic exits. The 50-day moving average sits at €0.0283, while the 200-day average is €2.3186, highlighting the catastrophic collapse. Year-to-date, ALEUP.PA stock has lost 91.95%, making it one of EURONEXT’s worst performers. This relentless decline reflects deteriorating fundamentals and investor confidence collapse in Europlasma S.A.

Europlasma S.A. Fundamentals: Deep Financial Distress

Europlasma S.A. operates in waste management and plasma torch systems but faces severe financial distress. The company reported negative net income per share of -€88.61, indicating massive operating losses. Operating profit margin stands at -47.22%, meaning the company loses money on every euro of revenue. Free cash flow per share is -€95.63, showing the firm burns cash rapidly. The current ratio of 0.80 signals liquidity concerns, as current liabilities exceed current assets. Debt-to-equity ratio is -0.91, reflecting negative equity. These metrics explain why track ALEUP.PA on Meyka for real-time updates shows persistent weakness.

Market Sentiment: Trading Activity and Liquidation Pressure

Trading activity in ALEUP.PA stock reveals severe liquidation pressure. Relative volume reached 4.16x normal levels, indicating forced selling by distressed holders. The Money Flow Index (MFI) at 57.32 suggests moderate selling pressure despite high volume. Williams %R indicator at -86.85 signals extreme oversold conditions, yet the stock continues falling. RSI at 42.71 shows weakness without bounce-back strength. The Stochastic oscillator (%K: 22.38, %D: 30.20) confirms downward momentum. These technical signals combined with surging volume paint a picture of institutional and retail investors exiting positions simultaneously, creating a cascade of selling.

Meyka AI Rating: ALEUP.PA Receives Grade B with Hold Suggestion

Meyka AI rates ALEUP.PA with a grade of B and suggests a Hold position, despite today’s collapse. The overall score of 62.78 factors in S&P 500 benchmark comparison (11%), sector performance (16%), industry comparison (16%), financial growth (12%), key metrics (16%), forecasts (8%), analyst consensus (14%), and fundamental growth (7%). This grade reflects mixed signals: strong ROE at 3.03% contrasts sharply with negative ROA at -0.52% and negative ROIC at -1.21%. The company’s DCF valuation score is 1 (Strong Sell), while ROE scores 5 (Strong Buy). These grades are not guaranteed and we are not financial advisors.

Price Forecast and Valuation Outlook

Meyka AI’s forecast model projects €0.11 monthly and €0.37 quarterly for ALEUP.PA stock, implying significant upside from current €0.018 levels. This represents potential gains of 511% monthly and 1,956% quarterly if forecasts materialize. However, these projections appear disconnected from fundamental reality. The company’s price-to-sales ratio of 0.0008 is extremely depressed, yet the enterprise value-to-sales ratio of 0.1148 suggests the market prices in continued distress. Forecasts are model-based projections and not guarantees. The massive gap between current price and forecast suggests either extreme undervaluation or model limitations in capturing the company’s deterioration.

Europlasma S.A. Business Model Under Pressure

Europlasma S.A., founded in 1992 and based in Pessac, France, operates three core segments: plasma solutions for industrial applications, hazardous waste valorization, and renewable energy from waste and biomass. The company employs 1,840 people and generates revenue of €215.38 per share annually. However, gross profit margin of just 0.57% reveals razor-thin profitability. Operating expenses consume 48.17% of revenue, leaving minimal room for profit. The company’s inability to convert revenue into earnings, combined with negative cash flow, suggests structural business challenges. Recent Europlasma S.A. stock data shows persistent weakness across all operational metrics, indicating the business model requires fundamental restructuring.

Final Thoughts

ALEUP.PA stock’s 18.18% collapse on April 20, 2026 reflects the harsh reality of Europlasma S.A.’s financial distress. The company faces negative earnings, negative cash flow, and deteriorating fundamentals that justify the market’s harsh valuation. With a market cap of just €48,231 and a stock price down 99.95% over one year, Europlasma S.A. represents a deeply troubled industrial firm. The surge in trading volume to 21 million shares signals panic liquidation rather than strategic buying. While Meyka AI’s forecast model projects upside to €0.11-€0.37, these projections appear optimistic given the company’s operational challenges. Investors should recognize ALEUP.PA stock as a high-risk, speculative position suitable only for those with extreme risk tolerance. The company’s survival depends on successful restructuring and operational turnaround, neither of which appears imminent based on current data.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.